EFVfull {CICI}

Pharmacoepidemiological HIV treatment data

Description

A hypothetical, simulated dataset which is line with the data-generating process of Schomaker et al. (2023) and inspired by the data of Bienczak et al. (2017); see references below. Compared to the dataset EFV, it contains all variables of the DAG in Figure 3 of Schomaker et al. (2023), also those which are not needed for identification of the counterfactual quantity of interest; that is, the expected viral suppression (VL) under a specific intervention on efavirenz concentrations (efv.0, efv.1, ...).

Usage

data(EFVfull)

Format

A data frame with 5000 observations on the following variables:

sex

The patient's sex

metabolic

Metabolism status (slow, intermediate, extensive) related to the single nucleotide polymorphisms in the CYP2B6 gene, which is relevant for metabolizing evafirenz and directly affects its concentration in the body.

log_age

log(age) at baseline

NRTI

Nucleoside reverse transcriptase inhibitor (NRTI) component of HIV treatment, i.e. abacavir, stavudine or zidovudine.

weight.0

log(weight) at time 0 (baseline)

comorbidity.0

Presence of co-morbidities at time 0 (baseline)

dose.0

Dose of efavirenz administered at time 0 (basline)

efv.0

Efavirenz concentration at time 0 (baseline)

VL.0

Elevated viral load (viral failure) at time 0 (baseline)

adherence.1

Adherence at time 1 (if 0, then signs of non-adherence)

weight.1

log(weight) at time 1

comorbidity.1

Presence of co-morbidities at time 1

dose.1

Dose of efavirenz administered at time 1

efv.1

Efavirenz concentration at time 1

VL.1

Elevated viral load (viral failure) at time 1

adherence.2

Adherence at time 2 (if 0, then signs of non-adherence)

weight.2

log(weight) at time 2

comorbidity.2

Presence of co-morbidities at time 2

dose.2

Dose of efavirenz administered at time 2

efv.2

Efavirenz concentration at time 2

VL.2

Elevated viral load (viral failure) at time 2

adherence.3

Adherence at time 3 (if 0, then signs of non-adherence)

weight.3

log(weight) at time 3

comorbidity.3

Presence of co-morbidities at time 3

dose.3

Dose of efavirenz administered at time 3

efv.3

Efavirenz concentration at time 3

VL.3

Elevated viral load (viral failure) at time 3

adherence.4

Adherence at time 4 (if 0, then signs of non-adherence)

weight.4

log(weight) at time 4

comorbidity.4

Presence of co-morbidities at time 4

dose.4

Dose of efavirenz administered at time 4

efv.4

Efavirenz concentration at time 4

VL.4

Elevated viral load (viral failure) at time

References

Schomaker M, McIlleron H, Denti P, Diaz I. (2023) Causal Inference for Continuous Multiple Time Point Interventions, ArXiv e-prints: https://arxiv.org/abs/2305.06645.

Bienczak et al. (2017) Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets, AIDS, 31:905-915

Examples

data(EFVfull)
str(EFVfull)